Benefits of Tecfidera
Tecfidera was studied in 2 clinical trials involving more than 2,600 people for 2 years each. In these studies, Tecfidera was compared against a placebo, or "fake" pill. This is a standard way to measure if a drug works as expected. Based on its clinical trials, Tecfidera was approved by the FDA to treat people with relapsing forms of multiple sclerosis. Find out more about trial results by clicking the green boxes below.
Reduced relapses
Call them relapses, flare-ups, or exacerbations. They're disruptive, and the goal is to reduce them. No MS medication completely gets rid of them, but people taking Tecfidera in a 2-year study had fewer relapses compared to placebo.
- Fewer people taking Tecfidera had relapses
- Relapse reductions over 2 years: percentage of people
- 27% of people taking Tecfidera experienced relapse compared with 46% of people taking placebo, making them 49% less likely to experience a relapse.
- This means that less than 3 out of 10 people taking Tecfidera experienced a relapse
People with MS tell us how important it is for them to stay as active and mobile as they possibly can. That's why we studied physical ability in people over a 2-year period. What we learned is that Tecfidera helped delay physical disability progression in people with relapsing MS
- 38% fewer people had disability progression compared to those taking placebo over 2 years
You don't necessarily feel brain lesions, but the fact they show up on an MRI scan means your MS has been active. We measured 3 different types of brain lesions, and for all 3 types, people taking Tecfidera had fewer lesions when compared to placebo over the 2-year study.
